drugset / Trial / NCT01296620

Ulimorelin Study of Efficacy and Safety (ULISES 008)

NCT01296620

Phase 3 Completed 330 enrolled Tranzyme, Inc. Norgine · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection

Timeline

Start
2011-02
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Ulimorelin Small molecule 160 ug/kg Intravenous
Subject Ulimorelin Small molecule 480 ug/kg Intravenous